resTORbio Inc is a clinical-stage biopharmaceutical company. It mainly focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company focuses on the mechanistic target of rapamycin (mTOR) pathway which regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1. It is also involved in the development of RTB101 which is a small molecule, potent TORC1 inhibitor. The company's pipeline products include RTB101 and RTB101+ everolimus.